Please Wait
Applying Filters...
menu
    • menu
    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    SPI Pharma has been solving formulation challenges using superior functional materials.

    Virtual Booth

    Contact Supplier

    Interquim comes from an international group of 50 companies active in the pharma, hospital, diagnostics, fine chemicals & feed sectors.

    Virtual Booth

    Contact Supplier

    Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.

    Virtual Booth

    Contact Supplier

    FAMAR CDMO- From early development to commercial manufacturing.

    Virtual Booth

    Contact Supplier

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Virtual Booth

    Contact Supplier

    Menu

    Sunitinib Malate

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 5,833Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Enforcement Report - Week of December 11, 2024
    Enforcement Report - Week of December 11, 2024

    11 Dec 2024

    // FDA

    https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-december-11-2024-90405.pdf

    FDA
    11 Dec 2024
    Share Share
    Eugia`s Generic Sunitinib Malate Receives Approval in the U.S.
    Eugia`s Generic Sunitinib Malate Receives Approval in the U.S.

    14 Mar 2024

    // FDA

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=218615

    FDA
    14 Mar 2024
    Share Share
    Eight-Year Data for Opdivo (nivolumab) Plus Yervoy (ipilimumab) Continue to Demonstrate Longest Survival Benefit vs. Sunitinib Reported in Patients with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma
    Eight-Year Data for Opdivo (nivolumab) Plus Yervoy (ipilimumab) Continue to Demonstrate Longest Survival Benefit vs. Sunitinib Reported in Patients with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma

    22 Jan 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240122188361/en

    BUSINESSWIRE
    22 Jan 2024
    Share Share
    Novugen's Generic Sunitinib Malate Receives Approval in the U.S.
    Novugen's Generic Sunitinib Malate Receives Approval in the U.S.

    21 Aug 2023

    // FDA

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=218012

    FDA
    21 Aug 2023
    Share Share
    Cogent Bio Announces Positive Lead-In Data from Ongoing Phase 3 PEAK Trial
    Cogent Bio Announces Positive Lead-In Data from Ongoing Phase 3 PEAK Trial

    03 Jun 2023

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2023/06/03/2681533/0/en/Cogent-Biosciences-Announces-Positive-Lead-In-Data-from-Ongoing-Phase-3-PEAK-Trial-Evaluating-Bezuclastinib-in-Combination-with-Sunitinib-in-Patients-with-Gastrointestinal-Stromal-.html

    GLOBENEWSWIRE
    03 Jun 2023
    Share Share
    Amber Specialty Added to Pfizer’s Limited Distribution Network
    Amber Specialty Added to Pfizer’s Limited Distribution Network

    03 Aug 2022

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20220803005649/en

    BUSINESSWIRE
    03 Aug 2022
    Share Share